Inlyta 5 mg

INLYTA 5 MG tablets are an oral medication used to manage certain types of cancer. This pharmaceutical, manufactured by Pfizer Canada ULC, is designed to support treatment protocols for advanced conditions.

INLYTA 5 MG tablets are typically used in the treatment of advanced renal cell carcinoma, a type of kidney cancer. This medication is often prescribed for patients who have experienced disease progression after prior therapy. The primary use of INLYTA is to help manage and slow the progression of cancer in these specific cases.

Common effects of INLYTA 5 MG tablets may include fatigue, diarrhea, and high blood pressure. Some users might also experience decreased appetite, nausea, and vomiting. These effects can vary from person to person, and it's important to monitor any changes in health while using this medication.

INLYTA 5 MG tablets should be handled with care and stored as directed. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Patients should be aware of potential side effects and report any severe or persistent symptoms to their healthcare provider.

INLYTA 5 MG tablets may interact with certain medications, including those metabolized by the liver's CYP3A4 enzyme. It is advisable to consult a healthcare professional before combining INLYTA with other medications, especially those known to affect liver function. Additionally, grapefruit and grapefruit juice should be avoided as they can impact the effectiveness of this medication.